New Home-Mid Content


The King's Thrombosis Centre is a leading multidisciplinary clinical and research group dedicated to the diagnosis and treatment of hypercoagulable conditions.

We are a designated Haemophilia Centre and were the first National Venous Thromboembolism (VTE) Exemplar Centre, reflecting our national leadership in the prevention and treatment of VTE. Our clinical trials unit works in partnership with industry to develop new treatments for VTE prevention and treatment.

More about the Centre


With the next generation of oral anticoagulants entering clinical practice, the FIRST registry will provide an important data tool to increase knowledge and improve the quality of care of patients with VTE.

More about the Registry


The King’s Thrombosis Centre runs this training course twice a year, which was developed to meet the educational needs of healthcare professionals involved in anticoagulation management. Click here to download an application form and agenda.

For further information, contact Dr Raj Patel


After being hosted at the King's Thrombosis Centre website since its launch in 2007, the website is now managed as part of the National VTE prevention Programme at NHS England. Click the image to access the site.

Latest News

  • Anticoagulation news items. Week commencing 25th November 2019
    Ultrasound-accelerated catheter-directed thrombolysis versus anticoagulation for the prevention of post-thrombotic syndrome (CAVA): a single-blind, multicentre, randomised trial The Lancet Haematology RCT (184) showed additional ultrasound-accelerated catheter-directed thrombolysis (urokinase) does not…
  • Anticoagulation news items. Week commencing 18th November 2019
    Optimizing heart failure management: anticoagulation, diuretic withdrawal, iron substitution, and novel inotropes European Heart Journal Review discusses management options for heart failure with reduced ejection fraction (HfrEF), whether anticoagulation would…
  • Anticoagulation news items. Week commencing 11th November 2019
    DTB Commentary: Intensive antiplatelet therapy with three agents does not reduce risk of another stroke Drug and Therapeutics Bulletin A commentary on the Triple Antiplatelets for Reducing Dependency after Ischaemic…